CMB International has released a research report highlighting WUXI BIO (02269)'s strong first-half performance, which prompted an upward revision of its full-year revenue growth guidance to 15%-18%. The firm has raised its target price for WUXI BIO from HK$39 to HK$60, while reiterating a "Buy" rating.
The bank has also upgraded its earnings forecasts for WUXI BIO, now projecting a 17.1% year-on-year increase in revenue and a 16.5% rise in adjusted net profit for 2026. This adjustment reflects the company's improved guidance and a positive outlook on sector demand.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments